Floatz logo

Brigatinib

ALK-Positive Anaplastic Large Cell Lymphoma

Princess Maxima Center for Pediatric OncologySmall moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the ALK-Positive Anaplastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Etoposide
Mingzhi Zhang
Phase 4BB
Crizotinib
Mingzhi Zhang
Phase 4BB
Adriamycin
Huiqiang Huang
Phase 2BB
Dexasone
Huiqiang Huang
Phase 2BB
Cyclophosphamide
Huiqiang Huang
Phase 2BB

View all 32 →

Same molecule, other indications

Brigatinib is also rated in:

cancerActive
B
Indicative · Phase 3
63 / 100
View asset →
non-small cell lung carcinomaActive
B
Indicative · Phase 3
60 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative · Phase 3
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →